Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial

Autor: Jaclyn A, Smith, Michael M, Kitt, Alan, Bell, Nicolas, Noulin, Anjela, Tzontcheva, Megan McGratty, Seng, Susan, Lu

Publikováno v: Smith, J A, Kitt, M M, Bell, A, Noulin, N, Tzontcheva, A, Seng, M M & Lu, S 2022, ' Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection : A Phase 2a, Randomized, Placebo-Controlled Trial ', Pulmonary therapy, vol. 8, no. 3, pp. 297-310 . https://doi.org/10.1007/s41030-022-00193-w

INTRODUCTION: Available therapies for acute cough, a condition frequently caused by a viral upper respiratory tract infection (URTI), have shown limited evidence of efficacy. Gefapixant, a P2X3-receptor antagonist, has demonstrated efficacy and safet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::038b3392d5b6562e2c888710db6b71b4
https://doi.org/10.1007/s41030-022-00193-w